Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
Author(s) -
Jacopo Giuliani,
Andrea Bonetti
Publication year - 2021
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.14
Subject(s) - osimertinib , epidermal growth factor receptor , lung cancer , drug resistance , drug , cancer research , gene , epidermal growth factor , medicine , biology , cancer , receptor , oncology , pharmacology , genetics , erlotinib
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom